Drug Topics

AUGUST 11, 2025

Amid the growing need for personalized medicine following events like the COVID-19 pandemic, pharmacists have significantly made their clinical authority known and are working hard to prove their roles within the greater health care team.

Specialty Pharmacies

Drug Topics

JULY 26, 2025

In the world of pharmacy management, success hinges on more than just dispensing medications—it's about creating a culture of communication, continuous learning, and emotional intelligence.

Specialty Pharmacies

Drug Topics

JUNE 30, 2025

Importance of Communication in Buprenorphine Initiation | APhA 2025. Pharmacy Buprenorphine Programs Can Increase OUD Treatment Access, But Barriers Limit Engagement. Drug Topics. March 18, 2025. Accessed June 30, 2025. Nowosielski B. Drug Topics. March 25, 2025. Accessed June 30, 2025.

Compounding

Drug Topics

JULY 15, 2025

Pharmacists play a vital role in helping patients understand and manage insulin therapy through clear communication, relatable analogies, and personalized education tailored to individual regimens and lifestyles.

Specialty Pharmacies

Drug Topics

AUGUST 8, 2025

Recent studies showed the positive impact of these pharmacists’ roles on team communication and patient outcomes. AI chatbots also enable efficient communication with patients and can generate alerts for the care team based on a patient’s response. Pharmacogenomic testing is also becoming more widespread.

Specialty Pharmacies

Drug Topics

JUNE 20, 2025

They stress that rebuilding trust is challenging and requires careful, empathetic communication. Experts discuss the recent dismissal of all 17 members of the Advisory Committee on Immunization Practices (ACIP), a panel that provides guidance to the CDC on vaccine recommendations.

Vaccines

Drug Topics

JUNE 18, 2025

They recommended approaching SDOH conversations with empathy, an understanding of community resources, and open communication with the health care team. 4 “We're talking about food security, we're talking about aging programs, we're talking about education, and community resources. Drug Topics. May 30, 2025.

Communication

Pharma Marketing Network

DECEMBER 4, 2024

Companies are investing heavily in digital tools to streamline communication and build stronger connections. Strategies like storytelling, personalized educational content, and two-way communication channels create trust and build loyalty. Patient-Centric Marketing Patients want to feel heard.

Communication

Pharmaceutical Technology

AUGUST 11, 2025

Buy Reports Newsletters PT News FDA gives Arvinas and Pfizer’s vepdegestrant NDA for breast cancer Vepdegestrant is an investigational, oral bioavailable PROteolysis TArgeting Chimera (PROTAC) medication. Credit: Gorodenkoff/Shutterstock.com. Give your business an edge with our leading industry insights.

FDA

Pharma Marketing Network

MARCH 27, 2025

The shift is largely due to changes in user behavior, regulatory clarity, and the demand for more personalized, real-time communication. Brands tiptoed around platforms like Facebook or Twitter, fearful of FDA repercussions, adverse event reporting, and lack of clear guidance. Social is no longer one-way communication.

HIPAA

PharmExec

AUGUST 1, 2025

Author(s): Nicholas Jacobus Key Takeaways Vizz, an aceclidine-based eye drop, is FDA-approved for presbyopia, enhancing near vision without myopic shifts. SHOW MORE LENZ Therapeutics celebrates FDA approval of Vizz, the first aceclidine eye drop for presbyopia.

FDA

Pharmaceutical Technology

JUNE 25, 2025

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid (BP), a condition that predominantly affects the elderly. In February 2025, the FDA accepted Dupixent’s supplemental biologics licence application (sBLA) for priority review.

FDA

Pharmaceutical Technology

JULY 23, 2025

The MHRA has recognised that some practices are better with more flexibility, and that in a technology-enabled world which allows better training, information and communication, flexibility can be enabled without compromising safety. We may still continue to send you service-related and other non-promotional communications.

Communication

Drug Topics

JULY 18, 2025

The FDA has approved a prefilled syringe format of the recombinant zoster vaccine Shingrix for the prevention of shingles, GSK said in a release. The FDA has approved a prefilled syringe format of the recombinant zoster vaccine Shingrix for the prevention of shingles, GSK said in a release. References 1. News Release. July 17, 2025.

Vaccines

PharmExec

JULY 31, 2025

This is what the FDA requires for botanical drug approval: evidence, consistency, and repeatability. Analytical chemistry, biomanufacturing, and stringent quality controls enable the mapping, measurement, and standardization of the full chemical fingerprint of a plant-based therapeutic.

Compounding

Pharmaceutical Technology

JULY 29, 2025

The US Food and Drug Administration (FDA) has granted approval for Ascendis Pharma’s Skytrofa (lonapegsomatropin-tcgd, developed as TransCon hGH), a prodrug of somatropin or human growth hormone (HGH), to treat adults with growth hormone deficiency (GHD). Credit: Andrei Kuzmik / Shutterstock.com. Sign up for our daily news round-up!

FDA

PharmExec

AUGUST 7, 2025

Compliance with evolving frameworks such as GxP, HIPAA, GDPR, and AI risk management guidance from NIST and FDA. Embedding information security and privacy-by-design principles into AI and data platforms.

Communication

The Checkup by Singlecare

FEBRUARY 17, 2025

Its not safe or effective, according to the Food and Drug Administration (FDA), and it may lead to serious health problems. Although these medications are effective, the FDA has not yet approved generic versions, meaning people can only get a prescription for semaglutide under its brand name. Is compounded semaglutide safe?

Compounding

Pharmaceutical Technology

JULY 22, 2025

Johnson & Johnson (J&J) has submitted a new drug application (NDA) seeking approval from the US Food and Drug Administration (FDA) for its oral peptide, icotrokinra, to treat moderate to severe plaque psoriasis (PsO) in adults and children aged 12 years and above. Credit: design_cam/Shutterstock.com.

FDA

Pharmaceutical Technology

JULY 30, 2025

This follows the ODD granted by the US Food and Drug Administration (FDA) and highlights MP1032’s potential as a first-in-class therapy that may reduce the need for high-dose corticosteroids, which can lead to serious side effects such as growth stunting, osteoporosis and metabolic issues.

Packaging

The Checkup by Singlecare

APRIL 29, 2025

Food and Drug Administration (FDA) in 2017 to help people with Type 2 diabetes manage their blood sugar levels. Eventually, the FDA also approved another form of semaglutide , Wegovy , specifically for weight management. So far, the existing studies dont find a significant increase in psychiatric adverse events compared to placebo.

Dosage

The FDA Law Blog

APRIL 13, 2025

no comparator arm), FOENIX-CCA2 was not capable of establishing improvement on time-to-event efficacy endpoints such as PFS or OS and, without an appropriate comparator, it is not possible to determine if the observed effect is attributable to LYTGOBI or to other factor(s), such as the natural history of the disease. The problem?

FDA

The Checkup by Singlecare

AUGUST 7, 2025

Statins are a class of medications prescribed to treat high cholesterol and reduce the risk of serious cardiovascular events like heart attacks and strokes. A meta-analysis found that statin therapy in people with diabetes reduced their risk of major cardiovascular events by 27%–30% compared to those not taking a statin.

Communication

Pharma Marketing Network

JUNE 16, 2025

These communications take into account a provider’s specialty, prescribing patterns, and even digital behavior. Tactics such as EHR alerts, native medical journal content, programmatic advertising, and virtual speaker events help maintain brand visibility without physical presence. Personalization is at the core of this evolution.

Communication

Pharmaceutical Technology

JUNE 10, 2025

MSD has received US Food and Drug Administration (FDA) approval for Enflonsia (clesrovimab-cfor) to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. Can pharma tariffs “Make America Manufacture Again”? Credit: MargJohnsonVA/Shutterstock.

FDA

PharmExec

AUGUST 7, 2025

News News Academy Multimedia Editorial Podcasts Editorial Videos Peer Exchange Profiles in Medicine Conferences Conference Coverage Conference Listing Publications Pharmaceutical Executive Partner Perspectives Resources Content Engagement Hubs E-Books Events Sponsored Podcasts Sponsored Videos Webcasts Whitepapers Subscribe Choose Specialty Corporate (..)

Communication

PharmExec

JULY 29, 2025

Register Free: [link] Event Overview: Join us in this gripping session where you will hear from experts at Novartis and Gartner as they discuss the increased adoption of AI in the life sciences industry and, in particular, the impact of AI on R&D processes. July 31st 2025 Can AI Accelerate Clinical Review at FDA?

Communication

The Checkup by Singlecare

APRIL 18, 2025

In fact, its kind of a jack-of-all-trades drug, approved by the Food and Drug Administration (FDA) to treat epilepsy, postherpetic neuralgia, and restless leg syndrome. It doesnt require immediate medical attention, but its important to communicate any side effects to a healthcare provider so they can address them.

Adverse Reactions

Pharmacy Times

AUGUST 11, 2025

Transitions of care, or the movement of patients between health care settings or providers, impose a significant cost on the health care system due to frequent adverse events and hospital readmissions. 2 Although various programs aim to mitigate these risks, pharmacist-driven initiatives have proven particularly effective.

Hospitals

Pharmacy Times

AUGUST 7, 2025

SHOW MORE The FDA intends to update opioid labels to highlight risks of addiction, overdose, and interactions, enhancing safety in pain management practices. Labels now emphasize the risks of higher doses and caution against abrupt discontinuation in dependent patients to prevent withdrawal and other harms.

Labelling

Pharmaceutical Technology

JUNE 12, 2025

Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.

Communication

Drug Topics

AUGUST 8, 2025

With a lack of effective communication in China’s health systems, researchers deemed implementation of a multidisciplinary collaboration model significantly difficult. Previous evidence has shown the unique ability of pharmacists to reduce the overall use and duration of antibiotic therapies by at least 15% among their patients.

Specialty Pharmacies

Drug Topics

JUNE 23, 2025

According to Roth, Johnson, and several other experts, the best way to conduct diabetes services is through collaboration and constant communication. Although each has specific advantages, utilizing the proper education, evidence, and recommendations will be crucial in improving diabetes outcomes. REFERENCE Johnson H, Roth H.

Community Pharmacies

Pharmaceutical Technology

JUNE 9, 2025

YolTech Therapeutics has received the US Food and Drug Administration (FDA) approval for its investigational new drug (IND) application for YOLT-101 to treat heterozygous familial hypercholesterolemia (HeFH). Credit: aipicte/Shutterstock. Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

FDA

Drug Topics

AUGUST 7, 2025

Direct communication empowers patients with the knowledge necessary to adhere to their regimens, understand the purpose of their treatments, and participate in their health care decisions. Their accessibility and frequent interactions with patients position them uniquely to provide in-depth information about medications.

Specialty Pharmacies

Pharmaceutical Technology

JULY 29, 2025

The safety profile remained consistent with previous studies, with no unexpected events observed. Efficacy was demonstrated across the full spectrum of axSpA, including both radiographic (r-axSpA) and non-radiographic (nr-axSpA) forms. Rinvoq also beat Jyseleca to the market in axSpA, having gained approval in the indication in 2022.

Packaging

Pharmaceutical Technology

JULY 31, 2025

Annabel Kartal Allen July 31, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The FDA has appointed George Tidmarsh as the temporary director of CBER after Vinay Prasad’s sudden exit. Image credit: -Oxford- via Getty Images. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?

FDA